Copy
 
End of November 2020 Financial Update for "Campaign for Cures" to Develop a COVID-19 Vaccine
The Institute has raised $169,536 of this year's goal of $325,000 to develop a novel and ethical COVID-19 vaccine.

While the federal government launched "Operation Warp Speed" (OWS) to produce several vaccine candidates, there are numerous concerns about these vaccines. First, six out of the eight vaccines from OWS are using an aborted fetal cell in either vaccine design, testing or manufacturing. There is insufficient public information on the remaining two vaccine candidates to determine whether they also used an aborted fetal cell line during development. The lead vaccines are being produced by Pfizer and Moderna, which will soon receive an Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA). Their vaccines use a synthetic message ribonucleic acid (mRNA) to produce the COVID-19 "spike protein". It is important to note that mRNA vaccines have never been approved for any prior infectious disease. mRNA vaccines theoretically create an immunity to the virus by delivering the gene of the spike protein into muscle tissue which, in turn, produces the spike protein and elicits an immune response. While no cell is required to produce a mRNA vaccine, aborted fetal cells were used during their testing. These two companies recently released a press release that their vaccines are over 90 percent effective. However, to date, that data has not been published in a peer-reviewed scientific journal, nor have these companies defined what they mean by effective. By comparison, influenza vaccines, which have been available for decades, rarely achieve 50 percent effectiveness. Further, prior vaccine efforts after the SARS 2002 outbreak led to an adverse reaction called antibody development enhancement (ADE) during animal testing. When animal subjects were vaccinated, they developed more severe lung disease than those animals that were not vaccinated upon ultimate exposure to the SARS virus. Additionally, there is a potential risk of spike protein toxicity because there is a peptide segment of the COVID-19 spike protein being used that has the same sequence as found in bacteria and viruses that is known to cause toxic shock. Thus, there is concern that these vaccines have been rushed to market without careful consideration of the potential side effects. Ordinarily, vaccines take years to develop.

The Pfizer vaccine requires storage at -70 degrees Celsius (-94 degrees Fahrenheit), while Moderna claims their vaccine can be stored at -20 degrees Celsius for 6 months or refrigerated temperature for 30 days or room temperature for only 12 hours. These rigorous temperature requirements significantly pose challenges in storing and distributing vaccines not only in developed countries, but it will be almost impossible to transport and store mRNA vaccines in poor developing countries where there is a lack of electricity and infrastructure.

The Institute has been flooded with calls around the world about the ethical concerns with the Pfizer and Moderna vaccines and are asking us when our vaccine will be ready. The Institute's vaccine is in preclinical development but we are making good progress. However, we need continued financial support. More importantly, we are creating innovations that are lacking in OWS vaccines. The Institute is developing two vaccine approaches: a novel subunit vaccine approach and an attenuated live vaccine. The latter approach will take more time than the former. The former approach is anticipated to have the following innovations: (1) free of aborted fetal cells at all steps of development; (2) immunity against multiple viral sites; (3) storage and transportation temperatures achievable at room temperature making it easier for distribution; and (4) removal of toxic shock peptide segments for greater safety.

Thus, we need your support. Please donate to this research. To donate, go to
https://www.jp2mri.org.
Donate
John Paul II Medical Research Institute
2500 Crosspark Rd, Suite W230
Coralville, IA 52241
Phone: (319) 688-7367         Fax: (319) 887-2870 
Email:
 info@jp2mri.org        https://www.jp2mri.org






This email was sent to r_b_haney@yahoo.com
why did I get this?    unsubscribe from this list    update subscription preferences
John Paul II Medical Research Institute · 2500 Crosspark Rd, Suite W230 · Coralville, IA 52241 · USA